Classification/NN
of/IN
Colon/NN
Cancer/NN
Patients/NNS
Based/VBN
on/IN
the/DT
Methylation/NN
Patterns/NN
of/IN
Promoters/NNS
./.
====================
Diverse/JJ
somatic/JJ
mutations/NNS
have/VBP
been/VBN
reported/VBN
to/TO
serve/VB
as/IN
cancer/NN
drivers/VBZ
./.
====================
Recently/RB
,/,
it/PRP
has/VBZ
also/RB
been/VBN
reported/VBN
that/IN
epigenetic/JJ
regulation/NN
is/VBZ
closely/RB
related/JJ
to/TO
cancer/NN
development/NN
./.
====================
However/RB
,/,
the/DT
effect/NN
of/IN
epigenetic/JJ
changes/NNS
on/IN
cancer/NN
is/VBZ
still/RB
elusive/JJ
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
analyzed/VBD
DNA/NN
methylation/NN
data/NNS
on/IN
colon/NN
cancer/NN
taken/VBN
from/IN
The/DT
Caner/NN
Genome/NN
Atlas/NNS
./.
====================
We/PRP
found/VBD
that/IN
several/JJ
promoters/NNS
were/VBD
significantly/RB
hypermethylated/VBN
in/IN
colon/NN
cancer/NN
patients/NNS
./.
====================
Through/IN
clustering/NN
analysis/NN
of/IN
differentially/RB
methylated/VBN
DNA/NN
regions/NNS
,/,
we/PRP
were/VBD
able/JJ
to/TO
define/VB
subgroups/NNS
of/IN
patients/NNS
and/CC
observed/VBN
clinical/JJ
features/NNS
associated/VBN
with/IN
each/DT
subgroup/NN
./.
====================
In/IN
addition/NN
,/,
we/PRP
analyzed/VBD
the/DT
functional/JJ
ontology/NN
of/IN
aberrantly/RB
methylated/VBN
genes/NNS
and/CC
identified/VBD
the/DT
G-protein-coupled/JJ
receptor/NN
signaling/NN
pathway/NN
as/IN
one/CD
of/IN
the/DT
major/JJ
pathways/NNS
affected/VBN
epigenetically/RB
./.
====================
In/IN
conclusion/NN
,/,
our/PRP$
analysis/NN
shows/VBZ
the/DT
possibility/NN
of/IN
characterizing/VBG
the/DT
clinical/JJ
features/NNS
of/IN
colon/NN
cancer/NN
subgroups/NNS
based/VBN
on/IN
DNA/NN
methylation/NN
patterns/NNS
and/CC
provides/VBZ
lists/NNS
of/IN
important/JJ
genes/NNS
and/CC
pathways/NNS
possibly/RB
involved/VBN
in/IN
colon/NN
cancer/NN
development/NN
./.
====================
Generally/RB
,/,
it/PRP
is/VBZ
known/VBN
that/IN
cancer/NN
is/VBZ
a/DT
result/NN
of/IN
somatic/JJ
mutations/NNS
in/IN
DNA/NN
./.
====================
These/DT
mutations/NNS
are/VBP
located/JJ
in/IN
genes/NNS
that/WDT
have/VBP
important/JJ
roles/NNS
in/IN
regulating/VBG
cell/NN
growth/NN
,/,
cell/NN
differentiation/NN
,/,
and/CC
DNA/NN
damage/NN
control/NN
[/(
12/CD
]/)
./.
====================
Over/RB
the/DT
past/NN
decades/NNS
,/,
many/JJ
cancer/NN
driver/RB
genes/NNS
have/VBP
been/VBN
found/VBN
by/IN
high-throughput/JJ
sequencing/NN
technology/NN
,/,
and/CC
thus/RB
,/,
the/DT
number/NN
of/IN
cancer/NN
driver/RB
genes/NNS
may/MD
have/VB
reached/VBN
the/DT
limit/VB
[/(
13/CD
]/)
./.
====================
Until/IN
now/RB
,/,
many/JJ
researchers/NNS
have/VBP
studied/VBN
the/DT
mechanism/NN
of/IN
carcinogenesis/NN
and/CC
highlighted/JJ
the/DT
biological/JJ
role/NN
of/IN
driver/RB
mutations/NNS
,/,
such/JJ
as/IN
TP53/NN
,/,
PIK3CA/NN
,/,
and/CC
KRAS/JJ
[/(
4/CD
]/)
./.
====================
However/RB
,/,
in/IN
many/JJ
types/NNS
of/IN
cancers/NNS
,/,
the/DT
etiology/NN
of/IN
cancer/NN
can/MD
not/RB
be/VB
explained/VBN
only/RB
by/IN
DNA/NN
mutations/NNS
./.
====================
Researchers/NNS
have/VBP
found/VBN
that/IN
epigenetic/JJ
factors/NNS
,/,
such/JJ
as/IN
DNA/NN
methylation/NN
and/CC
histone/NN
modification/NN
,/,
also/RB
contribute/VBP
to/TO
cancer/NN
formation/NN
and/CC
development/NN
[/(
5/CD
]/)
./.
====================
Epigenetic/JJ
factors/NNS
are/VBP
dynamic/JJ
modifications/NNS
that/IN
can/MD
change/VB
the/DT
state/NN
of/IN
gene/NN
expression/NN
or/CC
regulate/VBP
expression/NN
rates/NNS
./.
====================
Some/DT
studies/NNS
have/VBP
shown/VBN
that/IN
a/DT
large/JJ
group/NN
of/IN
cancer/NN
patients/NNS
have/VBP
both/DT
globally/RB
low/JJ
and/CC
high/JJ
levels/NNS
of/IN
DNA/NN
methylation/NN
(/(
hypomethylation/NN
and/CC
hypermethylation/NN
,/,
respectively/RB
)/)
in/IN
specific/JJ
promoter/NN
regions/NNS
[/(
6/CD
]/)
./.
====================
Based/VBN
on/IN
analysis/NN
of/IN
DNA/NN
methylation/NN
data/NNS
,/,
they/PRP
listed/VBD
a/DT
few/JJ
cancer-related/JJ
genes/NNS
that/WDT
carry/VBP
significant/JJ
methylation/NN
changes/NNS
as/IN
biomarkers/NNS
[/(
7/CD
]/)
./.
====================
However/RB
,/,
the/DT
biological/JJ
meaning/VBG
of/IN
these/DT
markers/NNS
is/VBZ
still/RB
not/RB
well/RB
known/VBN
./.
====================
Hence/RB
,/,
in/IN
this/DT
study/NN
,/,
we/PRP
used/VBD
colon/NN
cancer/NN
(/(
COAD/NN
)/)
datasets/NNS
taken/VBN
from/IN
The/DT
Caner/NN
Genome/NNP
Atlas/IN
(/(
TCGA/NN
)/)
to/TO
observe/VB
a/DT
CG/NN
dense/JJ
region/NN
called/VBN
CpG/NN
islands/VBZ
(/(
CGIs/NNS
)/)
that/WDT
showed/VBD
significant/JJ
aberrations/NNS
in/IN
DNA/NN
methylation/NN
and/CC
also/RB
analyzed/VBD
changes/NNS
in/IN
DNA/NN
methylation/NN
patterns/NNS
to/TO
further/RBR
understand/VB
the/DT
relationship/NN
between/IN
epigenetic/JJ
changes/NNS
and/CC
cancer/NN
mechanism/NN
./.
====================
TCGA/NN
COAD/NN
DNA/NN
methylation/NN
datasets/NNS
and/CC
expression/NN
datasets/NNS
====================
Both/DT
methylation/NN
and/CC
gene/NN
expression/NN
data/NNS
were/VBD
obtained/VBN
from/IN
the/DT
TCGA/NN
Data/NNS
Portal/JJ
(/(
https/NNS
:/:
//tcga-data.nci.nih.gov/tcga//JJ
)/)
./.
====================
We/PRP
collected/VBD
COAD/NN
Level/JJ
3/CD
(/(
pre-processed/VBN
)/)
JHU-USC/NN
HumanMethylation450/CD
data/NNS
for/IN
methylation/NN
and/CC
UNC/NN
illuminaHiSeq_RNASeqV2/NN
data/NNS
for/IN
gene/NN
expression/NN
./.
====================
We/PRP
neglected/VBD
a/DT
normalization/NN
step/NN
for/IN
both/DT
datasets/NNS
,/,
since/IN
they/PRP
were/VBD
pre-processed/VBN
and/CC
normalized/VBD
by/IN
uploaded/VBN
groups/NNS
./.
====================
We/PRP
matched/VBD
methylation/NN
and/CC
gene/NN
expression/NN
data/NNS
by/IN
patient/NN
header/NN
ID/NN
using/VBG
the/DT
TCGA/NN
barcode/NN
./.
====================
Beta-value/DT
,/,
a/DT
value/NN
of/IN
the/DT
ratio/NN
of/IN
the/DT
methylated/JJ
probe/NN
intensity/NN
and/CC
the/DT
overall/JJ
intensity/NN
,/,
was/VBD
used/VBN
to/TO
represent/VB
the/DT
methylation/NN
percentage/NN
./.
====================
Gene/NN
expression/NN
fold-change/VBP
was/VBD
calculated/VBN
by/IN
taking/VBG
scaled/VBN
estimate/NN
values/NNS
,/,
multiplying/JJ
by/IN
106/CD
(/(
transcripts/NNS
per/IN
million/NN
,/,
TPM/NN
)/)
,/,
adding/VBG
1/CD
to/TO
each/DT
normal/JJ
and/CC
tumor/NN
TPM/NN
,/,
and/CC
then/RB
taking/VBG
the/DT
log2/NN
value/NN
of/IN
tumor/NN
and/CC
normal/JJ
per/FW
gene/NN
./.
====================
Differential/JJ
methylation/NN
and/CC
expression/NN
analysis/NN
and/CC
clustering/NN
====================
To/TO
get/VB
differential/JJ
DNA/NN
methylation/NN
values/NNS
between/IN
normal/JJ
tissue/NN
and/CC
tumor/NN
,/,
we/PRP
averaged/VBD
all/DT
normal/JJ
samples/NNS
using/VBG
annotated/JJ
probes/NNS
./.
====================
For/IN
CGI/NN
analysis/NN
purposes/NNS
,/,
we/PRP
intersected/VBD
each/DT
beta-value/IN
for/IN
a/DT
total/JJ
of/IN
485,579/CD
probes/NNS
from/IN
the/DT
methylation/NN
data/NNS
to/TO
the/DT
CGI/NN
location/NN
(/(
provided/VBN
by/IN
University/JJ
of/IN
California/NN
Santa/NN
Cruz/NN
[/(
UCSC/NN
]/)
)/)
,/,
averaged/JJ
them/PRP
using/VBG
CGIs/NNS
,/,
and/CC
then/RB
subtracted/VBD
the/DT
averaged/JJ
DNA/NN
methylation/NN
value/NN
of/IN
normal/JJ
samples/NNS
from/IN
individual/JJ
tumor/NN
samples/NNS
./.
====================
To/TO
focus/VB
on/IN
the/DT
effect/NN
of/IN
promoter/NN
CGIs/NNS
,/,
we/PRP
selected/VBD
CGIs/NNS
that/DT
fell/JJ
only/RB
into/IN
our/PRP$
defined/VBN
promoter/NN
region/NN
,/,
which/WDT
covers/VBZ
the/DT
transcription/NN
start/NN
site/NN
±/CD
1/CD
kb/NN
./.
====================
Using/VBG
this/DT
boundary/NN
,/,
a/DT
total/JJ
of/IN
15,966/CD
promoter/NN
CGIs/NNS
were/VBD
counted/VBN
./.
====================
The/DT
methylation/NN
distribution/NN
pattern/NN
of/IN
promoter/NN
CGIs/NNS
was/VBD
plotted/VBN
by/IN
taking/VBG
the/DT
mean/JJ
promoter/NN
CGI/NN
methylation/NN
from/IN
the/DT
entire/JJ
tumor/NN
and/CC
normal/JJ
sample/JJ
datasets/NNS
./.
====================
To/TO
get/VB
differentially/RB
methylated/VBN
promoter/NN
CGIs/NNS
,/,
the/DT
averaged/JJ
normal/JJ
data/NNS
were/VBD
used/VBN
as/IN
a/DT
reference/NN
,/,
since/IN
there/EX
were/VBD
no/DT
significant/JJ
variations/NNS
among/IN
normal/JJ
samples/NNS
./.
====================
Differential/JJ
patient/NN
data/NNS
were/VBD
calculated/VBN
by/IN
subtracting/VBG
this/DT
reference/NN
from/IN
each/DT
patient/NN
methylation/NN
data/NNS
point/VBP
(/(
n/NN
=/JJ
297/CD
)/)
./.
====================
In/IN
order/NN
to/TO
define/VB
the/DT
differential/JJ
methylation/NN
cutoff/JJ
,/,
we/PRP
referred/VBD
to/TO
the/DT
methylation/NN
distribution/NN
pattern/NN
between/IN
normal/JJ
samples/NNS
and/CC
tumors/NNS
./.
====================
Methylated/JJ
CGI/NN
annotated/JJ
genes/NNS
varied/VBN
in/IN
their/PRP$
methylation/NN
percentage/NN
throughout/IN
the/DT
patients/NNS
./.
====================
Therefore/RB
,/,
differentially/RB
methylated/VBN
CGIs/NNS
were/VBD
identified/VBN
as/IN
absolute/JJ
difference/NN
of/IN
0.3/CD
in/IN
beta-values/NNS
in/IN
at/IN
least/JJS
30/CD
%/NN
of/IN
total/JJ
patients/NNS
to/TO
obtain/VB
a/DT
broader/JJR
range/NN
for/IN
gene/NN
selection/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
We/PRP
grouped/VBD
COAD/NN
patients/NNS
by/IN
clustering/NN
their/PRP$
CGI/NN
differential/JJ
methylation/NN
values/NNS
using/VBG
Cluster3.0/NN
(/(
http/NN
:/:
//bonsai.hgc.jp/~mdehoon/software/cluster/software.htm/JJ
)/)
./.
====================
We/PRP
specifically/RB
used/VBN
hierarchical/JJ
clustering/NN
using/VBG
the/DT
Euclidean/JJ
distance/NN
similarity/NN
metric/JJ
and/CC
the/DT
complete/JJ
linkage/NN
clustering/NN
method/NN
,/,
which/WDT
grouped/VBD
the/DT
patients/NNS
the/DT
best/JJS
./.
====================
To/TO
reveal/VB
the/DT
direct/JJ
methylation/NN
effect/NN
on/IN
gene/NN
expression/NN
,/,
we/PRP
selected/VBD
an/DT
expression/NN
dataset/NN
that/DT
only/RB
matched/VBN
with/IN
the/DT
methylation/NN
dataset/NN
,/,
as/IN
well/RB
as/IN
a/DT
normal/JJ
sample-tumor/JJ
paired/JJ
dataset/NN
(/(
n/NN
=/JJ
26/CD
)/)
./.
====================
We/PRP
then/RB
aligned/VBD
26/CD
paired/JJ
patient/NN
data/NNS
to/TO
the/DT
each/DT
group/NN
,/,
divided/VBN
by/IN
the/DT
CGI/NN
methylation/NN
clustering/NN
value/NN
./.
====================
Expression/NN
level/NN
of/IN
patients/NNS
in/IN
each/DT
group/NN
were/VBD
averaged/VBN
by/IN
genes/NNS
and/CC
then/RB
plotted/VBD
with/IN
mean/JJ
values/NNS
and/CC
95/CD
%/NN
confidence/NN
levels/NNS
./.
====================
Gene/NN
ontology/NN
analysis/NN
and/CC
pathway/NN
analysis/NN
====================
To/TO
gain/VB
a/DT
biological/JJ
understanding/NN
from/IN
the/DT
selected/VBN
genes/NNS
,/,
we/PRP
carried/VBD
out/RP
gene/NN
ontology/NN
analysis/NN
and/CC
pathway/NN
analysis/NN
using/VBG
InnateDB/NN
[/(
8/CD
]/)
./.
====================
A/DT
hypergeometric/JJ
algorithm/NN
was/VBD
selected/VBN
,/,
and/CC
Benjamini-Hochberg/NN
was/VBD
used/VBN
for/IN
the/DT
correction/NN
method/NN
./.
====================
All/DT
three/CD
ontology/JJ
results/NNS
,/,
including/VBG
molecular/JJ
function/NN
,/,
cellular/JJ
components/NNS
,/,
and/CC
biological/JJ
process/NN
,/,
were/VBD
considered/VBN
./.
====================
Pathway/NN
results/NNS
were/VBD
also/RB
sourced/VBD
from/IN
various/JJ
databases/NNS
,/,
including/VBG
Integrating/JJ
Network/NN
Objects/NNS
with/IN
Hierarchies/NNS
(/(
INOH/NN
)/)
,/,
Reactome/NN
,/,
Kyoto/NNP
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
(/(
KEGG/NN
)/)
,/,
Pathway/NN
Interaction/NN
Database/NN
(/(
PID/NN
)/)
NIC/NN
,/,
and/CC
PID/NN
BioCarta/NNP
./.
====================
Significant/JJ
Gene/NN
Ontology/NN
(/(
GO/NN
)/)
terms/NNS
and/CC
pathways/NNS
were/VBD
selected/VBN
based/VBN
on/IN
p-value/NN
selection/NN
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
We/PRP
combined/VBD
functionally/RB
redundant/JJ
GO/NN
terms/NNS
,/,
because/IN
genes/NNS
that/WDT
contained/VBD
such/JJ
ontologies/IN
were/VBD
nearly/RB
identical/JJ
./.
====================
Pathways/NNS
were/VBD
sorted/VBN
and/CC
grouped/VBD
by/IN
their/PRP$
functional/JJ
similarity/NN
of/IN
each/DT
pathway/NN
./.
====================
From/IN
the/DT
many/JJ
selected/VBN
pathways/NNS
,/,
we/PRP
focused/VBD
on/IN
pathways/NNS
that/WDT
were/VBD
previously/RB
found/VBN
to/TO
be/VB
involved/VBN
in/IN
tumorigenesis/NN
./.
====================
G/NN
protein-coupled/JJ
receptor/NN
(/(
GPCR/NN
)/)
signaling/NN
pathway-related/JJ
genes/NNS
were/VBD
gathered/VBN
from/IN
the/DT
InnateDB/NN
and/CC
KEGG/NN
pathways/NNS
,/,
and/CC
we/PRP
indicated/VBD
the/DT
hypermethylated/JJ
genes/NNS
involved/VBN
in/IN
GPCR-related/JJ
signaling/NN
./.
====================
Cluster/NN
pattern/NN
of/IN
DNA/NN
methylation/NN
of/IN
promoter/NN
CGI/NN
and/CC
COAD/NN
patients/NNS
====================
From/IN
the/DT
TCGA/NN
data/NNS
portal/JJ
,/,
we/PRP
collected/VBD
array-based/VBN
DNA/NN
methylation/NN
data/NNS
of/IN
279/CD
patients/NNS
./.
====================
We/PRP
then/RB
derived/VBN
differential/JJ
DNA/NN
methylation/NN
values/NNS
between/IN
tumor/NN
and/CC
averaged/JJ
normal/JJ
samples/NNS
./.
====================
Differential/JJ
methylation/NN
values/NNS
of/IN
single-base/JJ
probes/NNS
were/VBD
averaged/VBN
by/IN
individual/JJ
CGIs/NNS
,/,
and/CC
the/DT
data/NNS
were/VBD
filtered/VBN
to/TO
indicate/VB
CGIs/NNS
with/IN
significant/JJ
changes/NNS
in/IN
methylation/NN
as/IN
described/VBN
in/IN
the/DT
``/NN
Methods/NNS
''/CD
section/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
We/PRP
also/RB
checked/VBD
the/DT
distribution/NN
of/IN
DNA/NN
methylation/NN
within/IN
promoter/NN
CGIs/NNS
between/IN
normal/JJ
and/CC
tumor/NN
samples/NNS
by/IN
taking/VBG
the/DT
mean/JJ
of/IN
each/DT
condition/NN
per/FW
CGI/NN
./.
====================
We/PRP
observed/VBD
that/IN
in/IN
general/JJ
,/,
promoter/NN
CGIs/NNS
were/VBD
hypermethylated/VBN
in/IN
COAD/NN
patients/NNS
in/IN
comparison/NN
to/TO
those/DT
in/IN
normal/JJ
samples/NNS
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
We/PRP
went/VBP
on/IN
to/TO
group/NN
COAD/NN
patients/NNS
based/VBN
on/IN
their/PRP$
differential/JJ
methylation/NN
status/NN
in/IN
promoter/NN
CGIs/NNS
using/VBG
clustering/NN
analysis/NN
./.
====================
Since/IN
it/PRP
is/VBZ
rare/JJ
to/TO
see/VB
promoter/NN
CGIs/NNS
being/VBG
differentially/RB
methylated/VBN
across/IN
an/DT
entire/JJ
group/NN
of/IN
patients/NNS
,/,
clustering/NN
was/VBD
focused/VBN
on/IN
selecting/VBG
CGIs/NNS
,/,
as/IN
well/RB
as/IN
identifying/VBG
patient/NN
groups/NNS
,/,
based/VBN
on/IN
their/PRP$
differential/JJ
methylation/NN
patterns/NNS
./.
====================
From/IN
our/PRP$
results/NNS
,/,
we/PRP
observed/VBD
a/DT
greater/JJR
number/NN
of/IN
hypermethylated/JJ
CGIs/NNS
than/IN
hypomethylated/JJ
CGIs/NNS
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
As/IN
indicated/VBD
by/IN
previous/JJ
studies/NNS
,/,
COAD/NN
follows/VBZ
a/DT
common/JJ
methylation/NN
pattern/NN
in/IN
cancer/NN
,/,
which/WDT
is/VBZ
hypermethylation/NN
of/IN
promoter/NN
CGIs/NNS
[/(
9/CD
]/)
./.
====================
We/PRP
were/VBD
also/RB
able/JJ
to/TO
distinguish/VB
three/CD
distinctive/JJ
clustered/VBN
groups/NNS
by/IN
their/PRP$
differential/JJ
methylation/NN
patterns/NNS
./.
====================
Group/NN
2/CD
(/(
n/NN
=/JJ
76/CD
)/)
showed/VBD
a/DT
much/RB
higher/JJR
level/NN
of/IN
methylation/NN
within/IN
selected/VBN
CGIs/NNS
than/IN
groups/NNS
1/CD
and/CC
3/CD
./.
====================
Group/NN
1/CD
showed/VBD
intermediate/JJ
differential/JJ
methylation/NN
./.
====================
To/TO
find/VB
the/DT
meaning/VBG
of/IN
each/DT
classified/VBN
patient/NN
group/NN
,/,
we/PRP
investigated/VBD
their/PRP$
respective/JJ
clinical/JJ
data/NNS
(/(
Table/JJ
1/CD
,/,
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
When/WRB
we/PRP
analyzed/VBD
the/DT
groups/NNS
by/IN
clinical/JJ
category/NN
,/,
such/JJ
as/IN
race/RB
,/,
age/NN
,/,
gender/RB
,/,
and/CC
tumor/NN
stage/NN
,/,
we/PRP
could/MD
not/RB
find/VB
any/DT
discriminating/JJ
factor/NN
among/IN
the/DT
three/CD
groups/NNS
./.
====================
However/RB
,/,
we/PRP
observed/VBD
a/DT
distinct/JJ
rate/NN
of/IN
metastasis/NN
in/IN
group/NN
2/CD
,/,
which/WDT
showed/VBD
the/DT
highest/JJS
level/NN
of/IN
hypermethylation/NN
./.
====================
At/IN
the/DT
same/JJ
time/NN
,/,
group/NN
2/CD
showed/VBD
a/DT
higher/JJR
rate/NN
of/IN
microsatellite/NN
instability/NN
(/(
MSI/NN
)/)
./.
====================
MSI/NN
is/VBZ
a/DT
hypermutable/JJ
phenotype/NN
caused/VBD
by/IN
impaired/JJ
DNA/NN
mismatch/NN
repair/NN
./.
====================
It/PRP
is/VBZ
already/RB
known/VBN
that/IN
MSI/NN
is/VBZ
associated/VBN
with/IN
hypermethylation/NN
in/IN
the/DT
promoter/NN
region/NN
of/IN
the/DT
MLH1/NN
gene/NN
[/(
10/CD
]/)
./.
====================
Although/IN
the/DT
MLH1/NN
gene/NN
was/VBD
not/RB
detected/VBN
in/IN
our/PRP$
filtered/JJ
data/NNS
,/,
we/PRP
surmised/VBD
that/DT
the/DT
MSI/NN
phenotype/NN
in/IN
COAD/NN
patients/NNS
can/MD
be/VB
affected/VBN
by/IN
both/CC
DNA/NN
hypermethylation/NN
and/CC
MLH1/NN
gene/NN
activity/NN
itself/PRP
./.
====================
Interestingly/RB
,/,
the/DT
tumor/NN
sites/NNS
differed/VBD
among/IN
the/DT
three/CD
groups/NNS
./.
====================
In/IN
group/NN
2/CD
,/,
the/DT
cecum/NN
was/VBD
the/DT
most/JJS
frequent/JJ
tumor/NN
site/NN
,/,
while/IN
the/DT
sigmoid/JJ
colon/NN
was/VBD
the/DT
least/JJS
frequent/JJ
site/NN
in/IN
comparison/NN
with/IN
groups/NNS
1/CD
and/CC
3/CD
./.
====================
These/DT
results/NNS
provide/VBP
a/DT
few/JJ
insights/NNS
about/IN
epigenetic/JJ
mechanisms/NNS
in/IN
COAD/NN
./.
====================
First/RB
,/,
the/DT
varying/VBG
methylation/NN
patterns/NNS
across/IN
COAD/NN
patient/NN
groups/NNS
imply/VBP
distinctive/JJ
epigenetic/JJ
cancer/NN
mechanisms/NNS
pertaining/VBG
to/TO
different/JJ
patient/NN
groups/NNS
./.
====================
This/DT
could/MD
lead/VB
to/TO
subtyping/VBG
COAD/NN
with/IN
varying/VBG
promoter/NN
CGI/NN
methylation/NN
status/NN
,/,
which/WDT
can/MD
be/VB
utilized/VBN
for/IN
treatment/NN
in/IN
patients/NNS
./.
====================
Second/RB
,/,
hypermethylated/JJ
promoter/NN
CGIs/NNS
were/VBD
enriched/VBN
in/IN
differentially/RB
methylated/VBN
region/NN
,/,
which/WDT
implies/VBZ
that/IN
the/DT
mechanism/NN
for/IN
COAD/NN
in/IN
promoter/NN
CGIs/NNS
might/MD
be/VB
driven/VBN
predominantly/RB
by/IN
methylating/VBG
factors/NNS
,/,
such/JJ
as/IN
DNA/NN
methyltransferases/NNS
./.
====================
Downregulated/JJ
gene/NN
expression/NN
in/IN
hypermethylated/JJ
promoter/NN
CGI/NN
group/NN
====================
To/TO
see/VB
whether/IN
DNA/NN
methylation/NN
directly/RB
affects/VBZ
gene/NN
expression/NN
within/IN
selected/VBN
CGIs/NNS
,/,
we/PRP
annotated/VBD
genes/NNS
to/TO
promoter/NN
CGIs/NNS
./.
====================
For/IN
the/DT
sake/NN
of/IN
accuracy/NN
,/,
we/PRP
selected/VBD
only/RB
gene/NN
expression/NN
datasets/NNS
that/DT
matched/VBN
the/DT
methylation/NN
data/NNS
./.
====================
We/PRP
further/RB
selected/VBN
datasets/NNS
that/DT
had/VBD
both/DT
normal/JJ
and/CC
tumor/NN
samples/NNS
from/IN
identical/JJ
patients/NNS
(/(
n/NN
=/JJ
26/CD
)/)
./.
====================
Since/IN
we/PRP
expected/VBD
different/JJ
gene/NN
expression/NN
levels/NNS
within/IN
the/DT
divided/VBN
groups/NNS
,/,
we/PRP
averaged/VBD
the/DT
expression/NN
level/NN
of/IN
patients/NNS
by/IN
each/DT
group/NN
./.
====================
We/PRP
then/RB
compared/VBD
the/DT
mean/JJ
values/NNS
of/IN
promoter-overlapping/VBG
genes/NNS
between/IN
the/DT
groups/NNS
to/TO
see/VB
the/DT
general/JJ
expression/NN
level/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
It/PRP
is/VBZ
well/RB
known/VBN
that/IN
the/DT
effect/NN
of/IN
promoter/NN
CGI/NN
methylation/NN
is/VBZ
repression/NN
of/IN
gene/NN
expression/NN
./.
====================
We/PRP
observed/VBD
that/IN
group/NN
2/CD
experienced/VBN
the/DT
highest/JJS
repression/NN
of/IN
gene/NN
expression/NN
levels/NNS
,/,
thus/RB
reflecting/VBG
the/DT
role/NN
of/IN
promoter/NN
CGI/NN
methylation/NN
as/IN
a/DT
gene-repressive/JJ
marker/NN
./.
====================
In/IN
comparison/NN
,/,
we/PRP
noted/VBD
the/DT
highest/JJS
overall/JJ
gene/NN
expression/NN
levels/NNS
in/IN
group/NN
3/CD
./.
====================
COAD/NN
patients/NNS
in/IN
less/RBR
hypermethylated/JJ
groups/NNS
,/,
however/RB
,/,
were/VBD
less/RBR
affected/VBN
by/IN
hypermethylation/NN
in/IN
their/PRP$
promoter/NN
region/NN
./.
====================
We/PRP
noted/VBD
that/IN
there/EX
were/VBD
some/DT
patients/NNS
in/IN
all/DT
groups/NNS
whose/WP$
gene/NN
expression/NN
was/VBD
not/RB
affected/VBN
by/IN
methylation/NN
./.
====================
We/PRP
assumed/VBD
that/IN
there/EX
were/VBD
not/RB
only/RB
epigenetic/JJ
factors/NNS
but/CC
many/JJ
other/JJ
varying/VBG
factors/NNS
among/IN
cancer/NN
patients/NNS
that/WDT
could/MD
result/VB
in/IN
regulation/NN
at/IN
individual/JJ
genes/NNS
./.
====================
This/DT
DNA/NN
methylation/NN
change/NN
in/IN
promoter/NN
CGIs/NNS
,/,
which/WDT
alters/VBZ
gene/NN
expression/NN
,/,
is/VBZ
called/VBN
epi-mutation/NN
[/(
11/CD
]/)
./.
====================
Using/VBG
this/DT
analogy/NN
,/,
some/DT
patients/NNS
were/VBD
epi-mutated/JJ
in/IN
aberrantly/RB
methylated/VBN
promoter/NN
CGIs/NNS
,/,
while/IN
others/NNS
were/VBD
not/RB
affected/VBN
significantly/RB
./.
====================
In/IN
general/JJ
,/,
we/PRP
were/VBD
able/JJ
to/TO
see/VB
that/DT
promoter/NN
CGI/NN
hypermethylation/NN
is/VBZ
mostly/RB
linked/VBN
to/TO
the/DT
overall/JJ
repression/NN
of/IN
gene/NN
expression/NN
,/,
confirming/VBG
the/DT
epi-mutation/NN
effect/NN
./.
====================
Epi-mutated/JJ
genes/NNS
and/CC
pathways/NNS
in/IN
COAD/NN
====================
To/TO
see/VB
the/DT
biological/JJ
function/NN
of/IN
hypermethylated/JJ
promoter/NN
CGI/NN
genes/NNS
,/,
we/PRP
performed/VBD
gene/NN
ontology/NN
analysis/NN
[/(
8/CD
]/)
./.
====================
Gene/NN
ontology/NN
analysis/NN
provides/VBZ
a/DT
functional/JJ
interpretation/NN
of/IN
biological/JJ
process/NN
,/,
molecular/JJ
function/NN
,/,
and/CC
cellular/JJ
component/NN
among/IN
selected/VBN
genes/NNS
./.
====================
The/DT
ontology/NN
results/NNS
included/VBD
mainly/RB
neural/JJ
development-related/VBN
terms/NNS
,/,
such/JJ
as/IN
synaptic/JJ
transmission/NN
and/CC
nervous/JJ
system/NN
development/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
Interestingly/RB
,/,
the/DT
gene/NN
ontology/NN
term/NN
of/IN
sequence-specific/JJ
DNA-binding/JJ
transcription/NN
factor/NN
activity/NN
was/VBD
found/VBN
./.
====================
This/DT
implies/VBZ
that/IN
a/DT
large/JJ
group/NN
of/IN
downstream/JJ
genes/NNS
that/WDT
are/VBP
targeted/VBN
by/IN
the/DT
affected/VBN
transcription/NN
factors/NNS
could/MD
have/VB
a/DT
potential/JJ
role/NN
in/IN
cancer/NN
initiation/NN
and/CC
development/NN
./.
====================
Additionally/RB
,/,
we/PRP
carried/VBD
out/RP
pathway/NN
analysis/NN
to/TO
further/RBR
understand/VB
cancer-related/JJ
biological/JJ
processes/NNS
affected/VBN
by/IN
epi-mutated/JJ
genes/NNS
(/(
Supplementary/JJ
Table/JJ
2/CD
)/)
./.
====================
In/IN
fact/NN
,/,
many/JJ
recent/JJ
cancer-related/JJ
pathways/NNS
are/VBP
found/VBN
with/IN
mutations/NNS
among/IN
patients/NNS
,/,
and/CC
this/DT
information/NN
is/VBZ
useful/JJ
for/IN
functional/JJ
studies/NNS
of/IN
cancer/NN
mechanisms/NNS
[/(
2/CD
]/)
./.
====================
We/PRP
attempted/VBD
to/TO
provide/VB
an/DT
extended/JJ
network/NN
that/DT
involves/VBZ
hypermethylated/JJ
promoter/NN
CGI/NN
genes/NNS
to/TO
expand/VB
our/PRP$
understanding/NN
of/IN
epi-mutational/JJ
pathways/NNS
in/IN
cancer/NN
./.
====================
Selected/VBN
pathways/NNS
with/IN
p-value/JJ
</JJR
0.05/CD
include/VBP
Wnt/NN
signaling/NN
,/,
the/DT
RAS/NN
pathway/NN
,/,
migration/NN
and/CC
invasion/NN
,/,
extracellular/JJ
matrix/NN
organization/NN
,/,
and/CC
cell/NN
adhesion/NN
./.
====================
These/DT
pathways/NNS
are/VBP
commonly/RB
related/JJ
to/TO
cancer/NN
proliferation/NN
and/CC
metastasis/NN
[/(
12/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
the/DT
pathways/NNS
previously/RB
mentioned/JJ
,/,
we/PRP
found/VBD
the/DT
following/VBG
pathways/NNS
to/TO
be/VB
distinctive/JJ
to/TO
only/RB
hypermethylated/JJ
promoter/NN
CGI/NN
genes/NNS
in/IN
COAD/NN
:/:
calcium/NN
signaling/NN
,/,
ion/NN
channel/NN
,/,
and/CC
GPCR/NN
signaling/VBG
;/:
especially/RB
interesting/VBG
is/VBZ
the/DT
observation/NN
of/IN
hypermethylation/NN
in/IN
many/JJ
ligands/NNS
and/CC
receptors/NNS
that/WDT
are/VBP
involved/VBN
in/IN
GPCR/NN
signaling/VBG
(/(
Fig/NN
./.
====================
4/CD
)/)
[/(
1314151617181920/CD
]/)
./.
====================
This/DT
implies/VBZ
that/IN
epigenetic/JJ
mechanisms/NNS
play/VBP
a/DT
role/NN
upstream/RB
of/IN
the/DT
pathway/NN
,/,
regulating/VBG
many/JJ
downstream/JJ
signaling/NN
pathways/NNS
that/WDT
are/VBP
involved/VBN
in/IN
cancer/NN
growth/NN
./.
====================
Epi-mutated/JJ
pathway/NN
analysis/NN
thus/RB
allows/VBZ
us/PRP
to/TO
find/VB
additional/JJ
cancer-related/JJ
pathways/NNS
that/WDT
have/VBP
not/RB
been/VBN
previously/RB
highlighted/JJ
by/IN
analyses/NNS
based/VBN
on/IN
somatic/JJ
mutations/NNS
./.
====================
Overall/RB
,/,
these/DT
results/NNS
suggest/VBP
the/DT
function/NN
of/IN
hypermethylation/NN
in/IN
promoter/NN
CGI/NN
genes/NNS
in/IN
colon/NN
cancer/NN
as/IN
a/DT
driver/RB
of/IN
transcriptional/JJ
regulation/NN
and/CC
developmental/JJ
events/NNS
and/CC
indicate/VBP
that/IN
epi-mutated/JJ
genes/NNS
are/VBP
involved/VBN
in/IN
regulating/VBG
various/JJ
cancer-related/JJ
pathways/NNS
,/,
like/IN
GPCR/NN
signaling/NN
,/,
in/IN
favor/JJ
of/IN
colon/NN
cancer/NN
development/NN
./.
====================
In/IN
contrast/NN
to/TO
somatic/JJ
mutations/NNS
,/,
epigenetic/JJ
changes/NNS
are/VBP
reversible/JJ
phenomena/NNS
./.
====================
Using/VBG
this/DT
property/NN
,/,
epigenetic/JJ
factors/NNS
can/MD
be/VB
therapeutic/JJ
targets/NNS
of/IN
cancer/NN
treatments/NNS
./.
====================
Until/IN
now/RB
,/,
DNA/NN
methylation/NN
inhibitors/NNS
,/,
such/JJ
as/IN
azacitidine/JJ
,/,
have/VBP
been/VBN
used/VBN
as/IN
one/CD
of/IN
many/JJ
cancer/NN
drugs/NNS
./.
====================
However/RB
,/,
this/DT
kind/NN
of/IN
drug/NN
is/VBZ
not/RB
able/JJ
to/TO
specify/VB
the/DT
target/NN
molecule/NN
and/CC
shows/VBZ
differential/JJ
drug/NN
effects/NNS
in/IN
individual/JJ
cancer/NN
patients/NNS
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
observed/VBD
impaired/JJ
DNA/NN
methylation/NN
in/IN
colon/NN
cancer/NN
patients—so-called/JJ
epi-mutation/NN
[/(
21/CD
]/)
./.
====================
We/PRP
can/MD
confirm/VB
that/IN
DNA/NN
methylation/NN
aberrations/NNS
in/IN
specific/JJ
promoter/NN
regions/NNS
were/VBD
widely/RB
distributed/VBN
in/IN
cancer/NN
patients/NNS
and/CC
that/IN
patient/NN
groups/NNS
can/MD
be/VB
divided/VBN
by/IN
the/DT
extent/NN
of/IN
DNA/NN
methylation/NN
change/NN
./.
====================
We/PRP
expect/VBP
that/DT
by/IN
introducing/VBG
the/DT
epi-mutation/NN
concept/NN
,/,
patients/NNS
of/IN
a/DT
certain/JJ
cancer/NN
type/NN
that/DT
is/VBZ
not/RB
explained/VBN
by/IN
somatic/JJ
mutations/NNS
can/MD
be/VB
diagnosed/VBN
more/RBR
sensitively/RB
./.
====================
Moreover/RB
,/,
the/DT
subgroups/NNS
of/IN
patients/NNS
will/MD
provide/VB
a/DT
clue/NN
for/IN
the/DT
different/JJ
drug/NN
effects/NNS
between/IN
individual/JJ
cancer/NN
patients/NNS
./.
====================
Further/RB
epi-mutation/NN
studies/NNS
in/IN
each/DT
cancer/NN
type/NN
will/MD
define/VB
cancer-specific/JJ
related/JJ
biological/JJ
pathways/NNS
,/,
and/CC
overall/JJ
,/,
these/DT
results/NNS
will/MD
help/VB
us/PRP
understand/VB
the/DT
cancer/NN
mechanisms/NNS
and/CC
develop/VBP
target-specific/JJ
cancer/NN
drugs/NNS
./.
====================
Workflow/IN
of/IN
the/DT
COAD/NN
data/NNS
analysis/NN
./.
====================
CGI/NN
,/,
CpG/NN
island/NN
;/:
COAD/NN
,/,
colon/NN
cancer/NN
;/:
TCGA/NN
,/,
The/DT
Caner/NN
Genome/NN
Atlas/NNS
./.
====================
(/(
A/NN
)/)
Differential/JJ
DNA/NN
methylation/NN
pattern/NN
in/IN
promoter/NN
CpG/NN
islands/NNS
(/(
CGIs/NNS
)/)
between/IN
colon/NN
cancer/NN
(/(
COAD/NN
)/)
patients/NNS
and/CC
normal/JJ
./.
====================
A/DT
distribution/NN
plot/NN
of/IN
mean/JJ
beta-value/JJ
between/IN
all/DT
tumor/NN
(/(
red/JJ
)/)
and/CC
all/DT
normal/JJ
(/(
blue/JJ
)/)
samples/NNS
./.
====================
X-axis/NN
indicates/VBZ
beta-value/IN
ranging/VBG
from/IN
0/CD
to/TO
1/CD
./.
====================
Y-axis/NN
indicates/VBZ
the/DT
density/NN
of/IN
accumulated/VBN
beta-values/NNS
./.
====================
(/(
B/NN
)/)
Differential/JJ
DNA/NN
methylation/NN
pattern/NN
in/IN
promoter/NN
CGIs/NNS
between/IN
COAD/NN
patients/NNS
and/CC
normal/JJ
./.
====================
A/DT
heatmap/NN
of/IN
clustered/VBN
differentially/RB
methylated/VBN
promoter/NN
CGIs/NNS
./.
====================
We/PRP
defined/VBD
promoter/NN
CGI/NN
that/DT
has/VBZ
±0.3/CD
differential/JJ
beta-value/NN
in/IN
at/IN
least/JJS
30/CD
%/NN
patients/NNS
as/IN
differentially/RB
methylated/VBN
promoter/NN
CGIs/NNS
./.
====================
X-axis/NN
represents/VBZ
individual/JJ
promoter/NN
CGIs/NNS
(/(
1,341/CD
CGIs/NNS
)/)
,/,
and/CC
Y-axis/NN
represents/VBZ
each/DT
patient/NN
./.
====================
(/(
n/NN
=/JJ
297/CD
)/)
./.
====================
Patients/NNS
are/VBP
divided/VBN
based/VBN
on/IN
hierarchical/JJ
clustering/NN
using/VBG
Euclidian/JJ
distance/NN
similarity/NN
metric/JJ
./.
====================
Scale/NN
bar/JJ
ranging/VBG
from/IN
-0.5/CD
to/TO
+0.5/CD
tumor-normal/JJ
beta-value/JJ
./.
====================
Expression/NN
comparison/NN
among/IN
the/DT
groups/NNS
of/IN
clustered/VBN
hypermethylated/JJ
promoter/NN
CpG/NN
islands/NNS
(/(
CGIs/NNS
)/)
./.
====================
Only/RB
the/DT
normal-tumor/NN
paired/JJ
,/,
and/CC
methylation-expression/NN
matched/VBN
patients/NNS
were/VBD
selected/VBN
for/IN
comparison/NN
of/IN
gene/NN
expression/NN
(/(
n/NN
=/JJ
26/CD
)/)
./.
====================
Patients/NNS
were/VBD
divided/VBN
into/IN
the/DT
previously/RB
clustered/VBN
groups/NNS
by/IN
promoter/NN
CGI/NN
methylation/NN
./.
====================
Expression/NN
fold/JJ
change/NN
(/(
Y-axis/NN
)/)
was/VBD
calculated/VBN
by/IN
log2/NN
(/(
T/N/NN
)/)
./.
====================
Genes/NNS
that/WDT
overlap/VBP
with/IN
hypermethylated/JJ
promoter/NN
CGI/NN
were/VBD
averaged/VBN
by/IN
each/DT
patient/NN
and/CC
each/DT
group/NN
./.
====================
Each/DT
bar/JJ
represents/VBZ
standard/JJ
error/NN
mean/NN
of/IN
each/DT
patient/NN
./.
====================
Right/NN
panel/NN
is/VBZ
DNA/NN
methylation/NN
changing/VBG
pattern/NN
of/IN
corresponding/JJ
individual/JJ
patients/NNS
./.
====================
T/NN
,/,
tomor/NN
;/:
N/NN
,/,
normal/JJ
./.
====================
Representation/NN
of/IN
G/NN
protein-coupled/JJ
receptor/NN
related/JJ
signaling/NN
pathway/NN
affected/VBN
by/IN
the/DT
hypermethylated/JJ
promoter/NN
CpG/NN
island/NN
(/(
CGI/NN
)/)
genes/NNS
./.
====================
Hypermethylated/JJ
promoter/NN
CGI/NN
genes/NNS
are/VBP
marked/JJ
as/IN
red/JJ
./.
====================
Clinical/JJ
data/NNS
of/IN
three/CD
patient/NN
groups/NNS
in/IN
colon/NN
cancer/NN
====================
Ontology/NN
analysis/NN
results/VBZ
from/IN
hypermethylated/JJ
pCGI/NN
genes/NNS
====================
